Where are we at?
No peer review
No deal on OA
No funding
No chairman
No positive MPS results to elicit a bid from 30 pharma who were in the data room
The 1.5 mg twice weekly results are highly variable with some endpoints show a worse result than placebo. This is a dosing only 25% less than “optimal”
FDA does not think the drug is safe. On balance of risk reward on 2mg they are highly sceptical
Years of frustration. A pumper that has no gumption to caution his readership to invest so he can recover his outlay.
done
Where we at?, page-655
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $101.4M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 28.5¢ | $30.05K | 104.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15088 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 19986 | 5 |
View Market Depth
| Last trade - 13.52pm 24/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |